SOURCE: China Aoxing Pharmaceutical Co., Inc.

April 20, 2009 08:00 ET

China Aoxing Pharmaceutical Company Receives GMP Certification for Tablet Dosage Form of Pharmaceutical Products

NEW YORK, NY--(Marketwire - April 20, 2009) - China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that it has received the Good Manufacturing Practice (GMP) certification for its recently opened tablet formulation and packaging production facility. The certificate of compliance has a five-year term and was issued by the State Food and Drug Administration (SFDA) following a site inspection.

"Good Manufacturing Practice" is a body of internationally accepted regulations set forth by drug agencies at many countries. GMP compliance ensures that pharmaceuticals, active ingredients and medical devices are produced and quality-controlled according to state-of-the-art standards.

"GMP compliance is the gold standard in quality assurance in the life science industry. It is a major achievement for us to receive this particular GMP certification in early 2009," said Juan Yue Han, Chairman and the CEO of China Aoxing. "This provides the foundation for the further development of China Aoxing. We are well positioned to manufacture pharmaceutical products in tablet dosage form in our modern production facility, as we are preparing for the launch of several important narcotic drugs in tablet dosage form in the foreseeable future, including Tilidine, Oxycodone, Buprenorphine and others, which provide well established medical benefit in treating cancer pain, moderate to severe pain, or related chronic health problems."

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines, addressing a very under-served and fast-growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-KSB for the year ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact Information

  • Contact:

    Wei Zhang
    Investor Relations
    China Aoxing Pharmaceutical Company, Inc.
    Email: chinaaoxing@gmail.com
    Telephone: 646 - 512 - 5662